Sooryanarayana Varambally

List of Publications by Year
in descending order

143 papers	35,692 citations	13865 67 h-index	9589 142 g-index
156 all docs	156 docs citations	156 times ranked	36920 citing authors

#	Article	IF	Citations
1	Global molecular alterations involving recurrence or progression of pediatric brain tumors. Neoplasia, 2022, 24, 22-33.	5.3	7
2	MS4A3 promotes differentiation in chronic myeloid leukemia by enhancing common Î²-chain cytokine receptor endocytosis. Blood, 2022, 139, 761-778.	1.4	7
3	UALCAN: An update to the integrated cancer data analysis platform. Neoplasia, 2022, 25, 18-27.	5.3	666
4	DCZ0415, a smallâ€molecule inhibitor targeting TRIP13, inhibits EMT and metastasis via inactivation of the FGFR4/STAT3 axis and the Wnt/Î²â€catenin pathway in colorectal cancer. Molecular Oncology, 2022, 16, 1728-1745.	4.6	13
5	Meta-analysis of the robustness of COVID-19 diagnostic kit performance during the early pandemic. BMJ Open, 2022, 12, e053912.	1.9	1
6	Proteogenomic characterization of 2002 human cancers reveals pan-cancer molecular subtypes and associated pathways. Nature Communications, 2022, 13, 2669.	12.8	78
7	Distinct Gene Expression Profiles of Matched Primary and Metastatic Triple-Negative Breast Cancers. Cancers, 2022, 14, 2447.	3.7	6
8	Reducing regorafenib toxicity by combining with dual JAK-HDAC inhibitor in colorectal cancer.. Journal of Clinical Oncology, 2022, 40, e15597-e15597.	1.6	0
9	Subcellular localization of EZH2 phosphorylated at T367 stratifies metaplastic breast carcinoma subtypes. Breast Cancer, 2021, 28, 496-505.	2.9	7
10	Mass-spectrometry-based proteomic correlates of grade and stage reveal pathways and kinases associated with aggressive human cancers. Oncogene, 2021, 40, 2081-2095.	5.9	22
11	NAB2-STAT6 Gene Fusions to Evaluate Primary/Metastasis of Hemangiopericytoma/Solitary Fibrous Tumors. American Journal of Clinical Pathology, 2021, 156, 906-912.	0.7	3
12	Comparative analysis of triple-negative breast cancer transcriptomics of Kenyan, African American and Caucasian Women. Translational Oncology, 2021, 14, 101086.	3.7	17
13	Collagen modifying enzyme P4HA1 is overexpressed and plays a role in lung adenocarcinoma. Translational Oncology, 2021, 14, 101128.	3.7	10
14	Comparative transcriptome analyses reveal genes associated with SARS-CoV-2 infection of human lung epithelial cells. Scientific Reports, 2021, 11, 16212.	3.3	15
15	The TGF-Î²/HDAC7 axis suppresses TCA cycle metabolism in renal cancer. JCI Insight, 2021, 6, .	5.0	9
16	Expression of MHC class I polypeptide-related sequence A (MICA) in colorectal cancer. Frontiers in Bioscience, 2021, 26, 765.	2.1	7
17	MS4A3 Promotes Differentiation in Chronic Myeloid Leukemia By Enhancing Common Î² Chain Cytokine Receptor Endocytosis. Blood, 2021, 138, 59-59.	1.4	0
18	14-3-3 proteins protect AMPK-phosphorylated ten-eleven translocation-2 (TET2) from PP2A-mediated dephosphorylation. Journal of Biological Chemistry, 2020, 295, 1754-1766.	3.4	21

#	Article	IF	Citations
19	Dysregulation of de novo nucleotide biosynthetic pathway enzymes in cancer and targeting opportunities. Cancer Letters, 2020, 470, 134-140.	7.2	53
20	TRIP13 promotes metastasis of colorectal cancer regardless of p53 and microsatellite instability status. Molecular Oncology, 2020, 14, 3007-3029.	4.6	24
21	PGC1Î± suppresses kidney cancer progression by inhibiting collagen-induced SNAIL expression. Matrix Biology, 2020, 89, 43-58.	3.6	17
22	PRDM16 suppresses HIF-targeted gene expression in kidney cancer. Journal of Experimental Medicine, 2020, 217, .	8.5	33
23	EZH2-Targeted Therapies in Cancer: Hype or a Reality. Cancer Research, 2020, 80, 5449-5458.	0.9	139
24	PAICS, a De Novo Purine Biosynthetic Enzyme, Is Overexpressed in Pancreatic Cancer and Is Involved in Its Progression. Translational Oncology, 2020, 13, 100776.	3.7	19
25	Fermentable fiber-induced hepatocellular carcinoma in mice recapitulates gene signatures found in human liver cancer. PLoS ONE, 2020, 15, e0234726.	2.5	4
26	Targeting P4HA1 with a Small Molecule Inhibitor in a Colorectal Cancer PDX Model. Translational Oncology, 2020, 13, 100754.	3.7	28
27	Fermentable fibers induce rapid macro- and micronutrient depletion in Toll-like receptor 5-deficient mice. American Journal of Physiology - Renal Physiology, 2020, 318, G955-G965.	3.4	3
28	PAICS, a Purine Nucleotide Metabolic Enzyme, is Involved in Tumor Growth and the Metastasis of Colorectal Cancer. Cancers, 2020, 12, 772.	3.7	32
29	MicroRNAâ€mediated inflammation and coagulation effects in rats exposed to an inhaled analog of sulfur mustard. Annals of the New York Academy of Sciences, 2020, 1479, 148-158.	3.8	10
30	Therapeutically actionable PAK4 is amplified, overexpressed, and involved in bladder cancer progression. Oncogene, 2020, 39, 4077-4091.	5.9	19
31	Integrative Epigenetic and Gene Expression Analysis of Renal Tumor Progression to Metastasis. Molecular Cancer Research, 2019, 17, 84-96.	3.4	37
32	Genome-wide DNA methylation encodes cardiac transcriptional reprogramming in human ischemic heart failure. Laboratory Investigation, 2019, 99, 371-386.	3.7	77
33	Expression and Role of Methylenetetrahydrofolate Dehydrogenase 1 Like (MTHFD1L) in Bladder Cancer. Translational Oncology, 2019, 12, 1416-1424.	3.7	21
34	Characterization of glycineâ€‹Nâ€‹acyltransferase like 1 (GLYATL1) in prostate cancer. Prostate, 2019, 79, 1629-1639.	2.3	12
35	MTHFD1L, A Folate Cycle Enzyme, Is Involved in Progression of Colorectal Cancer. Translational Oncology, 2019, 12, 1461-1467.	3.7	42
36	Pseudogene Associated Recurrent Gene Fusion in Prostate Cancer. Neoplasia, 2019, 21, 989-1002.	5.3	15

#	Article	IF	Citations
37	Inhibition of Hedgehog signaling reprograms the dysfunctional immune microenvironment in breast cancer. OncoImmunology, 2019, 8, 1548241.	4.6	76
38	The combined survival effect of codon 72 polymorphisms and p53 somatic mutations in breast cancer depends on race and molecular subtype. PLoS ONE, 2019, 14, e0211734.	2.5	7
39	Ferritin Light Chain Confers Protection Against Sepsis-Induced Inflammation and Organ Injury. Frontiers in Immunology, 2019, 10, 131.	4.8	64
40	Pan-cancer molecular subtypes revealed by mass-spectrometry-based proteomic characterization of more than 500 human cancers. Nature Communications, 2019, 10, 5679.	12.8	358
41	Largeâ€scale profiling of serum metabolites in African American and European American patients with bladder cancer reveals metabolic pathways associated with patient survival. Cancer, 2019, 125, 921-932.	4.1	42
42	Molecular Correlates of Metastasis by Systematic Pan-Cancer Analysis Across The Cancer Genome Atlas. Molecular Cancer Research, 2019, 17, 476-487.	3.4	28
43	Histone Methyltransferase EZH2: A Therapeutic Target for Ovarian Cancer. Molecular Cancer Therapeutics, 2018, 17, 591-602.	4.1	71
44	Gene Expression Profiling of Advanced Penile Squamous Cell Carcinoma Receiving Cisplatin-based Chemotherapy Improves Prognostication and Identifies Potential Therapeutic Targets. European Urology Focus, 2018, 4, 733-736.	3.1	18
45	miR-34a Regulates Expression of the Stathmin-1 Oncoprotein and Prostate Cancer Progression. Molecular Cancer Research, 2018, 16, 1125-1137.	3.4	51
46	Chemotherapy induces secretion of exosomes loaded with heparanase that degrades extracellular matrix and impacts tumor and host cell behavior. Matrix Biology, 2018, 65, 104-118.	3.6	172
47	Wnt receptor Frizzled 8 is a target of ERG in prostate cancer. Prostate, 2018, 78, 1311-1320.	2.3	25
48	A Role for De Novo Purine Metabolic Enzyme PAICS in Bladder Cancer Progression. Neoplasia, 2018, 20, 894-904.	5.3	50
49	Loss of RUNX3 expression is an independent adverse prognostic factor in diffuse large B-cell lymphoma. Leukemia and Lymphoma, 2017, 58, 179-184.	1.3	6
50	Amplified centrosomes and mitotic index display poor concordance between patient tumors and cultured cancer cells. Scientific Reports, 2017, 7, 43984.	3.3	20
51	Development of Peptidomimetic Inhibitors of the ERG Gene Fusion Product in Prostate Cancer. Cancer Cell, 2017, 31, 532-548.e7.	16.8	85
52	Prostate Cancer: An Update on Molecular Pathology with Clinical Implications. European Urology Supplements, 2017, 16, 253-271.	0.1	2
53	UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses. Neoplasia, 2017, 19, 649-658.	5.3	4,166
54	Expression and Role of PAICS, a De Novo Purine Biosynthetic Gene in Prostate Cancer. Prostate, 2017, 77, 10-21.	2.3	37

#	Article	IF	Citations
55	Prostate Cancer Imaging and Biomarkers Guiding Safe Selection of Active Surveillance. Frontiers in Oncology, 2017, 7, 256.	2.8	16
56	MicroRNA-101 regulated transcriptional modulator SUB1 plays a role in prostate cancer. Oncogene, 2016, 35, 6330-6340.	5.9	74
57	Genomic and Epigenomic Alterations in Cancer. American Journal of Pathology, 2016, 186, 1724-1735.	3.8	130
58	Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nature Medicine, 2016, 22, 298-305.	30.7	1,193
59	Cancer mediates effector T cell dysfunction by targeting microRNAs and EZH2 via glycolysis restriction. Nature Immunology, 2016, 17, 95-103.	14.5	310
60	EZH2 Upregulation Is Associated with Unfavorable Prognosis in Diffuse Large B-Cell Lymphoma through Potential RUNX3 Downregulation. Blood, 2016, 128, 5301-5301.	1.4	0
61	Increased Expression of EZH2 Is Associated with Inferior Survival in Primary Central Nervous System Diffuse Large B-Cell Lymphoma. Blood, 2016, 128, 4216-4216.	1.4	0
62	Association between Hepatitis C Virus Infection, p53 Phenotypes, and Gene Variants of Adenomatous Polyposis Coli in Hepatocellular Carcinomas. , 2016, 2016, .		0
63	Role and regulation of coordinately expressedde novopurine biosynthetic enzymesPPATandPAICSin lung cancer. Oncotarget, 2015, 6, 23445-23461.	1.8	80
64	The kinase activity of the Ser/Thr kinase BUB1 promotes TGF-Î² signaling. Science Signaling, 2015, 8, ra1.	3.6	72
65	Amplified centrosomes may underlie aggressive disease course in pancreatic ductal adenocarcinoma. Cell Cycle, 2015, 14, 2798-2809.	2.6	22
66	TRIP13 promotes error-prone nonhomologous end joining and induces chemoresistance in head and neck cancer. Nature Communications, 2014, 5, 4527.	12.8	129
67	The miR-124-Prolyl Hydroxylase P4HA1-MMP1 axis plays a critical role in prostate cancer progression. Oncotarget, 2014, 5, 6654-6669.	1.8	82
68	Prostate Cancer Genomics: Progress and Promise. European Urology, 2013, 64, 577-578.	1.9	1
69	Characterization of the EZH2-MMSET Histone Methyltransferase Regulatory Axis in Cancer. Molecular Cell, 2013, 49, 80-93.	9.7	130
70	Targeting the link between late pregnancy and breast cancer. ELife, 2013, 2, e01926.	6.0	4
71	The Enzymatic Activity of Apoptosis-inducing Factor Supports Energy Metabolism Benefiting the Growth and Invasiveness of Advanced Prostate Cancer Cells. Journal of Biological Chemistry, 2012, 287, 43862-43875.	3.4	19
72	Inhibition of histone methylation arrests ongoing graft-versus-host disease in mice by selectively inducing apoptosis of alloreactive effector T cells. Blood, 2012, 119, 1274-1282.	1.4	70

#	Article	IF	Citations
73	Role of Transcriptional Corepressor CtBP1 in Prostate Cancer Progression. Neoplasia, 2012, 14, 905-IN8.	5.3	59
74	Role of dutasteride in preâ€clinical ETS fusionâ€positive prostate cancer models. Prostate, 2012, 72, 1542-1549.	2.3	13
75	Therapeutic Targeting of SPINK1-Positive Prostate Cancer. Science Translational Medicine, 2011, 3, 72ra17.	12.4	140
76	Targeting of microRNA-142-3p in dendritic cells regulates endotoxin-induced mortality. Blood, 2011, 117, 6172-6183.	1.4	132
77	The tumor suppressor gene rap1GAP is silenced by miR-101-mediated EZH2 overexpression in invasive squamous cell carcinoma. Oncogene, 2011, 30, 4339-4349.	5.9	95
78	Mechanistic Rationale for Inhibition of Poly(ADP-Ribose) Polymerase in ETS Gene Fusion-Positive Prostate Cancer. Cancer Cell, 2011, 19, 664-678.	16.8	397
79	Coordinated Regulation of Polycomb Group Complexes through microRNAs in Cancer. Cancer Cell, 2011, 20, 187-199.	16.8	191
80	TMPRSS2â€“ERG-Mediated Feed-Forward Regulation of Wild-Type ERG in Human Prostate Cancers. Cancer Research, 2011, 71, 5387-5392.	0.9	42
81	Characterization of KRAS Rearrangements in Metastatic Prostate Cancer. Cancer Discovery, 2011, 1, 35-43.	9.4	91
82	Inhibition of Histone Methylation Arrests Ongoing Graft-Versus-Host Diseases in Mice by Selectively Inducing Apoptosis of Alloreactive Effector T Cells. Blood, 2011, 118, 820-820.	1.4	0
83	Re: Florian Jentzmik, Carsten Stephan, Kurt Miller, et al. Sarcosine in Urine after Digital Rectal Examination Fails as a Marker in Prostate Cancer Detection and Identification of Aggressive Tumours. Eur Urol 2010;58:12â€“8. European Urology, 2010, 58, e29-e30.	1.9	17
84	An Integrated Network of Androgen Receptor, Polycomb, and TMPRSS2-ERG Gene Fusions in Prostate Cancer Progression. Cancer Cell, 2010, 17, 443-454.	16.8	743
85	The neuronal repellent SLIT2 is a target for repression by EZH2 in prostate cancer. Oncogene, 2010, 29, 5370-5380.	5.9	75
86	Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nature Medicine, 2010, 16, 793-798.	30.7	436
87	Antibody-Based Detection of ERG Rearrangement-Positive Prostate Cancer. Neoplasia, 2010, 12, 590-IN21.	5.3	305
88	Induced Chromosomal Proximity and Gene Fusions in Prostate Cancer. Science, 2009, 326, 1230-1230.	12.6	334
89	AGTR1 overexpression defines a subset of breast cancer and confers sensitivity to losartan, an AGTR1 antagonist. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 10284-10289.	7.1	140
90	Tomlins et al. reply. Nature, 2009, 457, E2-E3.	27.8	6

#	Article	IF	Citations
91	Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature, 2009, 457, 910-914.	27.8	1,944
92	An integrative approach to reveal driver gene fusions from paired-end sequencing data in cancer. Nature Biotechnology, 2009, 27, 1005-1011.	17.5	69
93	RHAMM (CD168) Is Overexpressed at the Protein Level and May Constitute an Immunogenic Antigen in Advanced Prostate Cancer Disease. Neoplasia, 2009, 11, 956-963.	5.3	76
94	Proteomic Interrogation of Androgen Action in Prostate Cancer Cells Reveals Roles of Aminoacyl tRNA Synthetases. PLoS ONE, 2009, 4, e7075.	2.5	54
95	Repression of E-cadherin by the polycomb group protein EZH2 in cancer. Oncogene, 2008, 27, 7274-7284.	5.9	526
96	The Role of SPINK1 in ETS Rearrangement-Negative Prostate Cancers. Cancer Cell, 2008, 13, 519-528.	16.8	303
97	Inhibition of CCN6 (Wnt-1-Induced Signaling Protein 3) Down-Regulates E-Cadherin in the Breast Epithelium through Induction of Snail and ZEB1. American Journal of Pathology, 2008, 172, 893-904.	3.8	60
98	Role of the TMPRSS2-ERG Gene Fusion in Prostate Cancer. Neoplasia, 2008, 10, 177-IN9.	5.3	608
99	Golgi Protein GOLM1 Is a Tissue and Urine Biomarker of Prostate Cancer. Neoplasia, 2008, 10, 1285-IN35.	5.3	89
100	Genomic Loss of microRNA-101 Leads to Overexpression of Histone Methyltransferase EZH2 in Cancer. Science, 2008, 322, 1695-1699.	12.6	995
101	A Fluorescence In situ Hybridization Screen for E26 Transformationâ€“Specific Aberrations: Identification of DDX5-ETV4 Fusion Protein in Prostate Cancer. Cancer Research, 2008, 68, 7629-7637.	0.9	139
102	Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 Gene Fusions in Prostate Cancer. Cancer Research, 2008, 68, 73-80.	0.9	244
103	A Polycomb Repression Signature in Metastatic Prostate Cancer Predicts Cancer Outcome. Cancer Research, 2007, 67, 10657-10663.	0.9	308
104	Tumor cell-selective regulation of NOXA by c-MYC in response to proteasome inhibition. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 19488-19493.	7.1	171
105	Effect of Epidermal Growth Factor Receptor Inhibitor Class in the Treatment of Head and Neck Cancer with Concurrent Radiochemotherapy In vivo. Clinical Cancer Research, 2007, 13, 2512-2518.	7.0	48
106	Autoantibody Profiles Reveal Ubiquilin 1 as a Humoral Immune Response Target in Lung Adenocarcinoma. Cancer Research, 2007, 67, 3461-3467.	0.9	86
107	Oncomine 3.0: Genes, Pathways, and Networks in a Collection of 18,000 Cancer Gene Expression Profiles. Neoplasia, 2007, 9, 166-180.	5.3	1,847
108	Molecular Concepts Analysis Links Tumors, Pathways, Mechanisms, and Drugs. Neoplasia, 2007, 9, 443-IN9.	5.3	124

#	Article	IF	Citations
109	Role of epidermal growth factor receptor degradation in gemcitabine-mediated cytotoxicity. Oncogene, 2007, 26, 3431-3439.	5.9	66
110	Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature, 2007, 448, 595-599.	27.8	743
111	Integrative Genomics Analysis Reveals Silencing of Î²-Adrenergic Signaling by Polycomb in Prostate Cancer. Cancer Cell, 2007, 12, 419-431.	16.8	204
112	Defining Aggressive Prostate Cancer Using a 12-Gene Model. Neoplasia, 2006, 8, 59-68.	5.3	90
113	ADAM15 Disintegrin Is Associated with Aggressive Prostate and Breast Cancer Disease. Neoplasia, 2006, 8, 319-329.	5.3	85
114	Differential proteomic alterations between localised and metastatic prostate cancer. British Journal of Cancer, 2006, 95, 425-430.	6.4	27
115	Enhancing the antitumor activity of ErbB blockade with histone deacetylase (HDAC) inhibition. International Journal of Cancer, 2006, 118, 1041-1050.	5.1	41
116	Selection and cloning of poly(rC)-binding protein 2 and Raf kinase inhibitor protein RNA activators of 2â€²,5â€²-oligoadenylate synthetase from prostate cancer cells. Nucleic Acids Research, 2006, 34, 6684-6695.	14.5	48
117	Nod1 acts as an intracellular receptor to stimulate chemokine production and neutrophil recruitment in vivo. Journal of Experimental Medicine, 2006, 203, 203-213.	8.5	199
118	A Systems Approach to Model Metastatic Progression: Figure 1.. Cancer Research, 2006, 66, 5537-5539.	0.9	9
119	Ataxia Telangiectasia Mutated Down-regulates Phospho-Extracellular Signal-Regulated Kinase 1/2 via Activation of MKP-1 in Response to Radiation. Cancer Research, 2006, 66, 11554-11559.	0.9	25
120	Nod1 acts as an intracellular receptor to stimulate chemokine production and neutrophil recruitment in vivo. Journal of Cell Biology, 2006, 172, iX-iX.	5.2	0
121	Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer. Science, 2005, 310, 644-648.	12.6	3,541
122	Probabilistic model of the human protein-protein interaction network. Nature Biotechnology, 2005, 23, 951-959.	17.5	380
123	Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell, 2005, 8, 393-406.	16.8	731
124	Î±-Methylacyl-CoA Racemase Protein Expression Is Associated with the Degree of Differentiation in Breast Cancer Using Quantitative Image Analysis. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 1418-1423.	2.5	51
125	Identification of GATA3 as a Breast Cancer Prognostic Marker by Global Gene Expression Meta-analysis. Cancer Research, 2005, 65, 11259-11264.	0.9	272
126	The Unfolded Protein Response Modulates Toxicity of the Expanded Glutamine Androgen Receptor*. Journal of Biological Chemistry, 2005, 280, 21264-21271.	3.4	53

#	Article	IF	Citations
127	Mechanisms of Enhanced Radiation Response following Epidermal Growth Factor Receptor Signaling Inhibition by Erlotinib (Tarceva). Cancer Research, 2005, 65, 3328-3335.	0.9	359
128	The Polycomb Group Protein EZH2 Impairs DNA Repair in Breast Epithelial Cells. Neoplasia, 2005, 7, 1011-1019.	5.3	86
129	Autoantibody Signatures in Prostate Cancer. New England Journal of Medicine, 2005, 353, 1224-1235.	27.0	581
130	The Role of Metastasis-Associated Protein 1 in Prostate Cancer Progression. Cancer Research, 2004, 64, 825-829.	0.9	126
131	Natural antibodies sustain differentiation and maturation of human dendritic cells. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 14210-14215.	7.1	100
132	Natural human polyreactive IgM induce apoptosis of lymphoid cell lines and human peripheral blood mononuclear cells. International Immunology, 2004, 16, 517-524.	4.0	33
133	Overexpression, Amplification, and Androgen Regulation of TPD52 in Prostate Cancer. Cancer Research, 2004, 64, 3814-3822.	0.9	145
134	JAGGED1 Expression Is Associated with Prostate Cancer Metastasis and Recurrence. Cancer Research, 2004, 64, 6854-6857.	0.9	310
135	Androgen-Independent Prostate Cancer Is a Heterogeneous Group of Diseases. Cancer Research, 2004, 64, 9209-9216.	0.9	816
136	C5a-Induced Gene Expression in Human Umbilical Vein Endothelial Cells. American Journal of Pathology, 2004, 164, 849-859.	3.8	152
137	EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 11606-11611.	7.1	1,482
138	Molecular Cross-talk between the TRAIL and Interferon Signaling Pathways. Journal of Biological Chemistry, 2002, 277, 575-585.	3.4	89
139	Î±-Methylacyl Coenzyme A Racemase as a Tissue Biomarker for Prostate Cancer. JAMA - Journal of the American Medical Association, 2002, 287, 1662.	7.4	565
140	Î±-Methylacyl-CoA Racemase: Expression Levels of this Novel Cancer Biomarker Depend on Tumor Differentiation. American Journal of Pathology, 2002, 161, 841-848.	3.8	121
141	Changes in Differential Gene Expression because of Warm Ischemia Time of Radical Prostatectomy Specimens. American Journal of Pathology, 2002, 161, 1743-1748.	3.8	138
142	The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature, 2002, 419, 624-629.	27.8	2,411
143	Delineation of prognostic biomarkers in prostate cancer. Nature, 2001, 412, 822-826.	27.8	1,551